文献速递核素与放射性配体治疗肿瘤 PET/CT

161Tb-Tb-PSMA在多中心177Lu-PSMA难治性mCRPC中的初步经验

Initial Multicenter Experience with [161Tb]Tb-PSMA in [177Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer: Preliminary Results.
PubMed 文献 · J Nucl Med · 2025-12-03

这项前瞻性多中心研究纳入7例对177Lu-PSMA治疗进展的mCRPC患者,均接受2周期161Tb-Tb-PSMA(每周期7.4 GBq,间隔6周)。4例(57%)达客观影像学缓解,4例(57%)PSA下降≥50%,仅见1-2级不良事件,无3级以上毒性,器官剂量分布良好。

要点

  • 161Tb-PSMA在177Lu-PSMA难治性mCRPC中显示57%影像学缓解和PSA50应答。
  • 治疗耐受良好,仅1-2级不良事件,无3级以上毒性。
  • 器官剂量学证实吸收剂量分布良好。

核心结论

  • 161Tb-Tb-PSMA在177Lu-PSMA治疗后进展的mCRPC患者中显示出有前景的分子和生化活性及良好安全性。

研究设计与样本

  • 前瞻性多中心研究纳入7例mCRPC患者,均既往接受雄激素受体通路抑制剂、紫杉类化疗及至少2周期177Lu-PSMA后进展。
  • 所有患者PSMA阳性且无18F-FDG不一致病灶,每例接受2周期161Tb-Tb-PSMA,每周期7.4 GBq,间隔6周。

主要发现

  • 7例中4例(57%)达客观影像学缓解(RECIP 1.0),4例(57%)PSA下降≥50%。
  • 仅见1-2级不良事件,无3级以上毒性;器官剂量学证实吸收剂量分布良好。

关键数值与推荐

  • 疗效评估采用68Ga-Ga-PSMA PET/CT按RECIP 1.0标准及PSA动力学。
  • 每周期给药活度为7.4 GBq,间隔6周,共2周期。
  • 治疗后剂量学采用SPECT/CT于4个时间点进行。

临床怎么用

  • 对于177Lu-PSMA治疗后进展且PSMA阳性、无FDG不一致病灶的mCRPC患者,161Tb-PSMA可作为候选治疗选择,但需进一步研究验证。

局限性

  • 样本量仅7例,为初步结果,需更大规模研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

161Tb is a theranostic radionuclide that emits both β- particles and Auger electrons with high linear energy transfer, potentially enhancing cytotoxicity in micrometastatic disease. We report the first multicenter clinical experience of [161Tb]Tb-PSMA in patients with metastatic castration-resistant prostate cancer (mCRPC) refractory to [177Lu]Lu-PSMA therapy. Methods: This prospective, multicenter study included 7 patients with mCRPC who had progressed despite prior androgen receptor pathway inhibitors, taxane-based chemotherapy, and at least 2 cycles of [177Lu]Lu-PSMA. All patients had PSMA-positive disease without any [18F]FDG-discordant lesions. Each received 2 cycles of [161Tb]Tb-PSMA (7.4 GBq per cycle, 6-wk interval). Response was assessed with [68Ga]Ga-PSMA PET/CT per RECIP 1.0 and prostate-specific antigen kinetics. Posttherapy dosimetry was performed using SPECT/CT imaging at 4 time points. Results: Of the 7 patients, 4 (57%) demonstrated objective imaging response and 4 (57%) showed at least a 50% decline in prostate-specific antigen levels. Treatment was well tolerated, with only mild adverse events (grades 1-2) and no toxicity greater than grade 3. Organ dosimetry confirmed favorable absorbed dose distributions. Conclusion: [161Tb]Tb-PSMA demonstrated promising molecular and biochemical activity with a favorable safety profile in patients who had progressed after [177Lu]Lu-PSMA therapy. These preliminary findings support further investigation of 161Tb-based radiopharmaceuticals as next-generation therapeutic options for mCRPC.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kucuk NO, Coskun N, Araz M, et al. Initial Multicenter Experience with [161Tb]Tb-PSMA in [177Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer: Preliminary Results. J Nucl Med. 2025. PMID: 41043996. doi:10.2967/jnumed.125.270952

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。